Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.

Bianca GrosserJake Emmerson Nic Gabriel Reitsam David CunninghamMatthew NankivellRuth E LangleyWilliam H AllumMartin TrepelBruno MärklHeike I Grabsch

Published in: British journal of cancer (2023)

The SARIFA status has clinical utility as prognostic biomarker in oesophagogastric cancer patients irrespective of treatment modality. Whilst underlying biological mechanisms warrant further investigation, the SARIFA status might be used to identify new drug targets, potentially enabling repurposing of existing drugs targeting lipid metabolism.

Keyphrases

clinical trial
study protocol
patients undergoing
cardiac surgery
phase iii
cancer therapy
randomized controlled trial
locally advanced
emergency department
drug induced
radiation therapy
fatty acid
combination therapy
drug delivery
open label